昭衍新藥(06127.HK)2022年淨利增長92.71%至10.74億元 擬10轉4派4元
格隆匯3月31日丨昭衍新藥(06127.HK)公佈,截至2022年12月31日止年度,公司收益為人民幣22.68億元,同比增長49.5%;公司權益股東應占年內溢利為人民幣10.74億元,同比增長92.7%,基本每股盈利為人民幣2.01元,擬向全體股東每10股轉增4股並分配現金紅利4元(含税)。
公司總體的發展戰略是:藥物非臨牀藥理毒理學評價業務為核心業務,穩步提升市場佔有率及海外影響力;圍繞核心業務,積極拓展上下游的業務能力,包括藥物早期發現業務,藥物篩選及成藥性評價業務、細胞檢定業務、臨牀CRO業務、臨牀檢測業務等,擴大實驗模型生產規模及生產能力,打造獨具特色的非臨牀安全性評價、臨牀試驗及相關服務和優質實驗模型供應的黃金產業鏈,提供一站式服務;以市場需求為導向,積極開發滿足創新藥物需求的新技術、新方法,形成新的服務優勢;進一步提升國際化服務能力,參與全球競爭;把公司建設成具有國際競爭力的綜合性CRO。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.